The conclusion of the 2025 AAMLS conference on 13th April marked a fruitful and inspiring gathering of medical laboratory experts from Taiwan and across Asia.

We deeply appreciate all your insightful contributions regarding the integration of DNlite testing into medical service laboratories. This advancement will help enhance primary healthcare settings, such as clinics, by supporting precision management for diabetes patients. As the majority of diabetes care is provided through primary healthcare, this topic is especially relevant and timely.

In Taiwan, the release of the latest national clinical practice guidelines for diabetic kidney disease (DKD) management has launched a campaign promoting precision management in DKD. Medical laboratory professionals widely acknowledge the vital role of early detection and risk stratification in improving DKD outcomes.

DNlite, a urine-based prognostic test for assessing renal function in DKD, has emerged as a promising option. By identifying the risk of kidney deterioration before significant changes in eGFR or albuminuria are evident, DNlite offers valuable advantages for early intervention and the development of personalized treatment strategies.


DNlite, a urine-based prognostic test for assessing renal function in DKD, has emerged as a promising option. By identifying the risk of kidney deterioration before significant changes in eGFR or albuminuria are evident, DNlite offers valuable advantages for early intervention and the development of personalized treatment strategies.